Genetic abnormalities in acute lymphoblastic leukemia

Published on October 29, 2015   38 min

You are viewing a talk that is a part of one of our comprehensive courses. Additional learning material: case studies, projects, workshops and recommended reading; multiple choice questions and suggested exam questions with model answers are available on application. Learn more

Other Talks in the Series: Cancer Genetics

My name is Ching-Hon Pui. I'm a pediatric oncologist at St. Jude Children's Research Hospital in Memphis, Tennessee, USA. This talk is about genetic abnormalities in acute lymphoblastic leukemia, focusing mainly in child cases. For the rest of the talk, I will mention the abbreviation, ALL.
ALL, as shown in the bone marrow smear on the left and as white column of sediment on the right, is the most common child cancer, representing a fourth of all cancers in children.
The treatment of children with ALL is one of the greatest success stories of the modern medicine. The five-year survival rage has increased from 20 percent in the early 1960s to over 90 percent today. The main reason for this remarkable achievement included effective treatment administered in controlled clinical trials, precise diagnosis and risk classification and improved support care. Because of the ease to obtain leukemia samples, laboratory studies of child ALL have revealed many of the principles underlying current knowledge of cancer cell biology, further boosting the treatment results. With standard chromosomal and FISH analysis,

Genetic abnormalities in acute lymphoblastic leukemia

Embed in course/own notes